Anubhav Srivastava is a Research Fellow in the Drug Delivery, Disposition and Dynamics (D4) research team at the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University. He received his B.Sc. (Honours) from the University of Delhi in 2005, M.Sc. in Biotechnology from the University of Abertay Dundee in 2006 and PhD in Molecular and Biochemical Parasitology from the University of Glasgow in 2014. His expertise lies in integrating molecular biology tools with omics technologies to solve problems faced in early drug discovery and development. He uses a combination of biochemistry, analytical chemistry and comprehensive data analysis methods to investigate the mode of action of novel drug candidates in order to expedite them through the developmental pipeline. His work also involves discovering new metabolic networks in infectious disease causing pathogens and identifying chokepoints in metabolic disorders for developing targeted therapeutic interventions.
Anubhav has consistently produced research publications of high quality showcasing the applications of advanced metabolomics and has presented his work at more than ten international conferences. Anubhav has won the CASS (Contributing to Australian Scholarship and Science) Foundation travel award for 2017, twice won the EVIMalaR OzMalNet travel award from the European Virtual institute of Malaria Research and three awards from the British Society for Parasitology. He also led the outreach and marketing arm for the Glasgow chapter of Oxbridge Biotech Roundtable, an international network of university chapters that bring academic and industrial scientists together.
Anubhav holds a PMP certification awarded by the Project Management Institute, USA. He currently manages multiple metabolomics projects in the Creek lab at MIPS and supervises the D4 cell culture facility with over seventy users. He is an active member of the governing committee of the Australian and New Zealand Metabolomics Network (ANZMN), the MIPS Early Career Researchers committee and the Victorian Infection and Immunity Network (VIIN) annual symposium committee. He has a keen interest in science communication and analysing the global business landscape for pharmaceuticals and diagnostics of future.
Abstracts this author is presenting: